BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib plus MEK inhibitor binimetinib plus anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer Meeting Abstract
| Authors: | Van Cutsem, E.; Cuyle, P.; Huijberts, S.; Schellens, J.; Elez, E.; Yaeger, R.; Fakih, M.; Montagut, C.; Peeters, M.; Desai, J.; Yoshino, T.; Ciardiello, F.; Wasan, H.; Maharry, K.; Christy-Bittel, J.; Gollerkeri, A.; Kopetz, S.; Grothey, A.; Tabernero, J. |
| Abstract Title: | BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib plus MEK inhibitor binimetinib plus anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer |
| Meeting Title: | ESMO 20th World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2018 Jun 20-23 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-06-01 |
| Start Page: | mdy149.026 |
| Language: | English |
| ACCESSION: | WOS:000439970900027 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy149.026 |
| Notes: | Meeting Abstract: O-027 -- Appears on page 109 of the abstract book -- Source: Wos |
